VFMCRP Touts Positive Phase 3 Results for Velphoro Study

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has released positive results from a late-stage trial evaluating Velphoro (PA21) for dialysis patients with hyperphosphatemia, a complication reducing kidney function in patients with chronic kidney disease (CKD).

The 286-person phase 3 study conducted in China assessed Velphoro vs. sevelamer carbonate for lowering and maintaining serum phosphorous in adult CKD patients. Those receiving Velphoro saw serum phosphorus levels decline faster than those in the sevelamer carbonate control group.

VFRMCRP expects to submit a new drug application to China’s National Medical Products Administration by the end of this year.